Fertility outcomes several years after urgent fertility preservation for breast cancer patients.

Breast cancer fertility preservation infertility live birth pregnancy

Journal

Fertility and sterility
ISSN: 1556-5653
Titre abrégé: Fertil Steril
Pays: United States
ID NLM: 0372772

Informations de publication

Date de publication:
26 Apr 2024
Historique:
received: 30 08 2023
revised: 22 04 2024
accepted: 22 04 2024
medline: 29 4 2024
pubmed: 29 4 2024
entrez: 28 4 2024
Statut: aheadofprint

Résumé

To study the fertility outcomes of women who tried to conceive after breast cancer treatment and fertility preservation. Retrospective observational, bicentric cohort study. All patients who had undergone fertility preservation before breast cancer treatment between January 2013, and July 2019 were included (n=844). The end-point date was March 1, 2022. Patients with missing data on pregnancy attempts after cancer diagnosis (n=195) were excluded from the pregnancy analysis. Cumulative incidences of pregnancy and live birth were calculated. For women who became pregnant, the time to conception was calculated between the first fertility preservation consultation and the estimated day of conception. For those who did not conceive, we considered the time between first fertility preservation consultation and the end-point date or the date of patient death. A Cox regression model was used to study the predictive factors of pregnancy and live birth. Among the 649 patients with available data on pregnancy attempts after breast cancer diagnosis, 255 (39.3% [35.5-43.2]) tried to conceive (median follow-up 6.5 years). Overall, 135 (52.9% [46.6-59.2]) of these patients achieved a pregnancy, mainly through unassisted conception (79.3% [72.8-84.8]), and 99 reported a live birth (representing 38.8% of patients who attempted conception). In our cohort, 48 months after the first fertility preservation consultation, the cumulative incidence of pregnancy was 33.1% ([27.6-37.9]). After adjustment for age, parity, type of chemotherapy administration and endocrine therapy, only multiparity at diagnosis and absence of chemotherapy were positive predictive factors of pregnancy after cancer. Of the 793 patients who had vitrified oocytes/embryos, 68 used them (27% [21.3-32.5] of the patients who tried to conceive), resulting in 8 live births (11.8% [5.2-21.9]). Women who used their cryopreserved oocytes/embryos were older at the first consultation of fertility preservation (HR 1.71(1.42-2.21)), and chose more often to vitrify embryos (HR 1.76(1.28-2.23). Although pregnancy rates after fertility preservation for breast cancer are low, most conceptions are achieved without medical assistance. Our findings provide useful information to advise women on the different techniques of fertility preservation, their efficacy and safety, as well as the relatively high chances of unassisted conception.

Identifiants

pubmed: 38679360
pii: S0015-0282(24)00265-6
doi: 10.1016/j.fertnstert.2024.04.031
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Maëliss Peigné (M)

AP-HP-Université Sorbonne Paris Nord - Jean Verdier Hospital- Department of reproductive medicine and fertility preservation, F 93143, Bondy, France.

Pauline Mur (P)

AP-HP - Université Paris-Saclay- Antoine Beclère Hospital, Department of Reproductive Medicine and Fertility Preservation, F 92140, Clamart, France.

Laëtitia Laup (L)

AP-HP-Université Sorbonne Paris Nord - Jean Verdier Hospital- Department of reproductive medicine and fertility preservation, F 93143, Bondy, France.

Anne-Sophie Hamy (AS)

Department of Medical Oncology, Institut Curie, Université Paris Cité, Paris, France.

Christophe Sifer (C)

AP-HP-Université Sorbonne Paris Nord - Jean Verdier Hospital- Embryology unit, F 93143, Bondy, France.

Anne Mayeur (A)

AP-HP-Université Paris-Saclay- Antoine Beclère Hospital, Histology-Embryology-Cytogenetic Laboratory, F 92140, Clamart, France.

Florence Eustache (F)

AP-HP-Université Sorbonne Paris Nord - Jean Verdier Hospital- CECOS, F 93143, Bondy, France.

Solmaz Sarandi (S)

AP-HP-Université Sorbonne Paris Nord - Jean Verdier Hospital- Embryology unit, F 93143, Bondy, France.

Claire Vinolas (C)

AP-HP-Université Sorbonne Paris Nord - Jean Verdier Hospital- Department of reproductive medicine and fertility preservation, F 93143, Bondy, France.

Sophia Rakrouki (S)

AP-HP-Université Sorbonne Paris Nord - Jean Verdier Hospital- Department of reproductive medicine and fertility preservation, F 93143, Bondy, France.

Alexandra Benoit (A)

AP-HP - Université Paris-Saclay- Antoine Beclère Hospital, Department of Reproductive Medicine and Fertility Preservation, F 92140, Clamart, France.

Michaël Grynberg (M)

AP-HP-Université Sorbonne Paris Nord - Jean Verdier Hospital- Department of reproductive medicine and fertility preservation, F 93143, Bondy, France; AP-HP - Université Paris-Saclay- Antoine Beclère Hospital, Department of Reproductive Medicine and Fertility Preservation, F 92140, Clamart, France.

Charlotte Sonigo (C)

AP-HP - Université Paris-Saclay- Antoine Beclère Hospital, Department of Reproductive Medicine and Fertility Preservation, F 92140, Clamart, France; Université Paris Saclay, Inserm, Physiologie et physiopathologie endocrinienne, F-94276, Le Kremlin-Bicêtre, France.

Classifications MeSH